Binding sites for high molecular weight kininogen (HK) and for factor Xlla are present in the Apple 1 (All and the A4 domains of factor XI, respectively. To define the roles of these two sites in surface-mediated factor-XI activation we prepared conformationally constrained synthetic peptides and recombinant A I domain (rAl) and determined their effects on the activation of factor XI by factor Xlla in the presence of HK and either kaolin or dextran sulfate. Surfacemediated factor-XI activation by factor Xlla was inhibited by a conformationally constrained A4 peptide (Ala3'7-Gl$59), by an A1 peptide (Phew-Se$B), and by rAl (Glu'-Serw). When used in combination at equimolar concentrations, rAl and A4 peptide were 10-fold more effective than either one alone in inhibiting surface-mediated activation of factor XI by fac-T IS WELL KNOWN THAT the initiation of the contact phase of intrinsic coagulation involves a complex interaction of proteins on negatively charged surfaces leading to the activation of factor IX. Human factor XI participates in the contact phase of blood coagulation and is involved in intermolecular interactions with factor XIIa, high molecular weight kininogen (HK), and factor IX."I7 Factor XI is a 160 kD homodimer consisting of two identical disulfide-linked polypeptide chains, each of which can be cleaved at a single peptide bond (Arg3h9-Ile370) by factor XIIa to give rise to factor XIa9. Factor XI circulates in plasma in a noncovalent complex with HK that is required for the binding of factor XI to negatively charged surfaces and its proteolytic activation to factor XIa.7~1h The molecular mechanisms of factor XI activation and expression of factor Xla enzymatic activity have been studied in detai1.1~6~10"s.17 From the sequence of a cDNA insert coding for factor XI, the primary structure has been elucidated.' Four tandem repeat sequences (Al, A2, A3, and A4 domains) or Apple domains, each encoded by two exons, are present in each heavy chain." We have identified a binding site for HK in the first (Al) of the four Apple domains:."' whereas a substrate binding site for factor IX was localized to the A2 domain4 and a binding site for factor XIIa was localized to the A4 domain.l9 The present study was undertaken to determine which domains are involved in The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.
T IS WELL KNOWN THAT the initiation of the contact phase of intrinsic coagulation involves a complex interaction of proteins on negatively charged surfaces leading to the activation of factor IX. Human factor XI participates in the contact phase of blood coagulation and is involved in intermolecular interactions with factor XIIa, high molecular weight kininogen (HK), and factor IX."I7 Factor XI is a 160 kD homodimer consisting of two identical disulfide-linked polypeptide chains, each of which can be cleaved at a single peptide bond (Arg3h9-Ile370) by factor XIIa to give rise to factor XIa9. Factor XI circulates in plasma in a noncovalent complex with HK that is required for the binding of factor XI to negatively charged surfaces and its proteolytic activation to factor XIa.7~1h The molecular mechanisms of factor XI activation and expression of factor Xla enzymatic activity have been studied in detai1.1~6~10"s.17 From the sequence of a cDNA insert coding for factor XI, the primary structure has been elucidated.' Four tandem repeat sequences (Al, A2, A3, and A4 domains) or Apple domains, each encoded by two exons, are present in each heavy chain." We have identified a binding site for HK in the first (Al) of the four Apple domains:."' whereas a substrate binding site for factor IX was localized to the A2 domain4 and a binding site for factor XIIa was localized to the A4 domain.l9 The present study was undertaken to determine which domains are involved in tor Xlla. The A4 peptide was a competitive inhibitor of factor Xlla amidolytic activity and a noncompetitive inhibitor of factor-XI activation by factor Xlla, whereas rAl and the A1 peptide did not inhibit factor Xlla. The rAl domain inhibited factor XI binding to HK, whereas the A4 peptide did not. We conclude that specific sequences exposed on the surfaces of the A1 (Valss-Lysm) and A4 (Ala3'7-Gl$50) domains of factor Xi act synergistically to promote surface-mediated factor-XI activation by factor Xlla in the presence of HK by binding factor XI to surface-bound HK (A1 domain) and by binding factor Xlla near the cleavage site (Arg369-lle370) of factor XI (A4 domain).
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the surface-mediated activation of factor XI. Experiments are presented that support the notion that specific sequences exposed on the surface of the A1 and A4 domains of factor XI promote surface-mediated factor XI activation by factor XIIa.
MATERIALS AND METHODS
PuriJication of coagulation proteins. Factor XI, purified from human plasma by immunoaffinity chromatography using a monoclonal antibody to factor XI,'4 had a specific activity of 250 U/mg protein. HK (specific activity, 15 U/mg) was purified by the method of Kerbiriou and Griffin." Human a-factor XIIa was prepared by the method of Shore" and was a generous gift of Drs Joseph D. Shore and M. Margarida Bemardo (Division of Biochemical Research, Henry Ford Hospital, Detroit, MI). The protein migrated at an apparent molecular weight (Mr) of 80 kD by sodium dodecylsulfatepolyacrylamide gel electrophoresis (SDS-PAGE) in the absence of reducing agents, whereas, in the presence of reducing agents, it migrated as a heavy chain of 50 kD Mr and a light chain of 30 kD Mr. The factor XIIa concentration in solution was estimated from its amidolytic activity. It hydrolyzed 3.78 X mol of the chromogenic substrate S-2302 (D-Pro-Phe-Arg-p-nitroanilide; Ortho Diagnostics, Raritan, NJ) per minute per microgram of protein at pH 8.0 and 37°C. Amidolytic activity was assayed using 0.12 m m o K S-2302 in 0.1 molL Tris, 0.15 molL NaC1, pH 8.0. The change in absorbence at 405 nm was measured during incubation at 37°C. All purified proteins appeared homogeneous by SDS-PAGE.
Preparation of recombinant AI (rAl) domain. Details of the expression of the rAl domain are reported elsewhere.*'" Briefly, the AI domain of factor XI was prepared in Escherichia coli, following amplification using the polymerase chain reaction with primers corresponding to the A1 domain and human factor XI cDNA. This factor XI cDNA, a 2. l-kb EcoRI fragment containing the complete factor XI cDNA coding sequence, is a gift from Drs Dominic W. Chung, Kazuo Fujikawa and Earl W. Davie (Department of Biochemistry, University of Washington, Seattle, WA). The resulting polymerase chain reaction amplification product, which was found to contain the correct nucleotide sequence, was ligated into the cloning site of the pQE-9 vector (Qiagen Inc, Chatsworth, CA) and was expressed and purified according to the protocols contained in the QIAexpress kit manual. The expressed and purified recombinant A1 domain contained an NH2 terminal amino acid sequence identical to that of factor XI, showed a single band on SDS-PAGE, and was refolded according to the method recorded below.
Peptide synthesis. Peptides were synthesized on an Applied Bio- Abbreviations: FXlla, factor Xlla; FXI, factor XI.
systems 430A peptide synthesizer (Applied Biosystems, Foster City, CA) by a modification of the procedure described by Kent and ClarkLewis" as previously de~cribed.'~ The sequences of the synthetic peptides used in this study and referred to in Table 1 are given in previous p u b l i c a t i~n s ?~~~~'~ Refolding and reduction and alkylation of peptides. To refold peptides containing cysteine residues, the peptide was dissolved in deionized water as a 0.1 mg/mL solution in a flask containing a stir bar. The pH was adjusted to 8.5 with NH,OH, and the solution was allowed to stir at 5°C for at least 3 days. After stirring, all the peptide was apparently still in solution. The resulting solution was lyophilized. All the lyophilized peptide was able to redissolve in high performance liquid chromatography (HPLC) grade water, and there was no particulate material apparent. Alternatively, peptides were reduced with dithiothreitol and alkylated with iodoacetamide as previously described., HPLC. The HPLC system used was from Waters (Waters 600 Gradient Module, Model 740 Data Module, Model 46K Universal Injector, and Lambda-Max Model 481 Detector; Milford, MA). The reverse phase chromatography described here was performed using a Waters C8 pBondapak Column, whereas gel filtration was performed using a Waters Protein-Pak 60 Column as previously de~cribed.~.'.'~ Characterization of synthetic peptides. All the peptides used in this study were examined by HPLC (both reverse-phase and gelfiltration), and all showed a single homogeneous peak (data not shown). When the refolded peptides were examined by HPLC (both reverse-phase and gel-filtration), single homogeneous peaks with identical retention times to the original mixtures were observed. This shows the presence of a single homogeneous mixture of refolded peptides and not a mixed population of diverse polymers. The results were the same after reduction and alkylation of these same peptides;
ie, single peaks with identical retention times to the original mixtures were observed by both reverse-phase and gel-filtration HPLC. In addition, all reduced and alkylated or refolded peptides were examined for free SH groups using the Ellman reagent (5,5'-dithiobis[2-nitrobenzoic acid]). It was determinedz4 that there was less than 0.02 mol of free SH per mol of peptide, which further verifies that these refolded peptides were homogeneous preparations consisting of intramolecular disulfide-bonded peptide.
Matrix-assisted laser desorption flash ionization (MALDI).
Mass spectrometry was used to assess homogeneity and molecular mass of each synthesized peptide. MALDI was performed as previously described." The spectra of synthesized peptides showed masses almost identical to calculated values (ie, within 0.5%). with a single ion species detected in each case. The calculated and observed masses of the synthesized peptides were as follows: Phes6-SerS6, 3404.5 and 3408.9; Ala'M-Ala'76, 4777.2 and 4787.7; AsnZ3'-ArgZM, 3425.8 and 3413.5; Ala"7-Gly3s0, 3457.2 and 3466.8; and AspZsoLysZ8', 1187.0 and 1182.2. Preparation and characterization of factor Xla. Purified factor XI was activated by incubation at 37°C with human factor XIIa as previously describedi4 to be used as a reference standard in assays of factor XIa generation. Gel electrophoresis in the presence of NaDodSO, of this preparation under reducing conditions showed two major bands of Mr 50 and 30 k D .
Factor XIIa assays. Factor XIIa was assayed using the chromogenic substrate S-2302 according to the procedure previously described?'
Assay of factor XI activation. The rate of factor XI activation by factor XIIa was determined as previously reported.' Human factor XI (0.17 pmol/L) was incubated with factor XIIa (0.017 pmol/L) in the presence of HK (0.07 pmoVL) and dextran sulfate (2 pglmL) or kaolin (0.5 mglmL) for 15 minutes at 37"C, and the rate of factor XIa generation was measured using the substrate S-2366 at 405 nm. The amidolytic assay of factor XIa was performed by a modification of the method of Scott et al.27 Factor XIa generation, in the experiments reported here, was quantitated from a standard curve prepared using purified factor XIa.
Effect of peptides on the rate of activation of factor XI by factor XIIa. The assay procedure was the same as described above, except factor XIIa and HK were incubated for 3 minutes at 37°C with either peptide or buffer solution before the addition of other components of the assay mixture.
RESULTS
Effects of heavy chain-derived peptides on the activation of factor XI by factor XIIa in the presence of HK and kaolin. It is well documented that factor XI circulates in plasma in a noncovalent complex with HK, and this interaction is necessary for the binding of factor XI to a negatively charged surface and for its efficient proteolytic activation to factor A1 domain of factor XI335 and a binding site for factor XIIa is present in the A4 domain," we examined the contributions of these two sites to the surface-mediated activation of factor XI by factor XIIa. Conformationally constrained synthetic peptides of the A1 and A4 domains of factor XI were tested for their effects on the activation of factor XI by factor XIIa in the presence of HK and kaolin. The results are presented in Fig 1 and summarized in Table 1 . Peptide Ala3'7-Gly350 from the A4 domain inhibited factor XI activation by factor XIIa by 50% at a concentration of 5 X mom, whereas peptide Phe56-Sep6 from the A1 domain inhibited factor XI activation by 50% at a concentration of l X m o m (Fig  1) . Moreover, the recombinant A1 domain (Glu'-Sergo) was required at a concentration of 5 X mom to achieve 50% inhibition. In contrast, a peptide derived from the A2 domain (Ala'34-Ala'76) required 200-fold higher concentrations than the A1 and A4 peptides to produce 50% inhibition of factor XI activation, ie, 1 X mom. Moreover, peptides from the A3 domain ( A~n~" -A r g~~~) and the other half of the A4 domain (A~p**o-Gl~*xx) also required concentrations more than 100-fold higher than the A1 and A4 domain peptides for similar effects. The inhibitory effects of these peptides are not unexpected given the 23% to 34% identity of these tandem repeats.' However, we have previously shown that the A2 domain peptide (Ala1"-Ala'76) inhibits factor IX activation by factor XIa with an inhibition constant (Ki) of 1 X m o L 4 The effects of negatively charged surface on amidolytic activity of factor XIIa. We have previously shown that the A4 domain of factor XI (peptide Ala3'7-Gly350) binds factor XIIa and is a competitive inhibitor of factor XIIa amidolytic activity (Ki = 3.8 pmoVL)." To better understand the surface-mediated activation of factor XI and to interpret the experiment presented in Fig 1, we examined the effect of the recombinant A1 peptide (Glu'-Serg0) on the amidolytic activity of factor XIIa both in the presence and absence of kaolin and HK (Fig 2) . Kaolin (0.5 mg/mL) was shown to inhibit (by -35%) the amidolytic activity of factor XIIa using the substrate S2302 in the absence of the recombinant A1 peptide (Gl~l-Ser'~). In the presence of recombinant AI peptide, HK, and kaolin, an even greater inhibition (85%) of amidolytic activity was observed. However, in the presence of HK and peptide in the absence of kaolin, no inhibition of amidolytic activity was observed. Because of this effect of kaolin on factor XIIa, we investigated another negatively charged surface, dextran sulfate. Dextran sulfate (2 mg/mL), either in the presence or the absence of HK, did not affect the amidolytic activity of factor XIIa (data not shown). Therefore, we used dextran sulfate in all our subsequent experiments on surface-mediated factor XI activation.
BAGLIA, SEAMAN, AND WALSH
Effect of AI and A4 peptides on the amidolytic activity of factor Xlla in the presence of dextran sulfate and HE(. Because we previously showed that the A4 peptide (Ala3I7-Gly350) is a competitive inhibitor of factor XIIa amidolytic activity suggesting that it binds near the active site of factor XIIa,I9 we determined whether the A4 peptide has a similar effect on surface-mediated factor XI activation by factor XIIa. We have shown" that the A4 peptide (Al~17-Gly7so) inhibits (by 50%) the amidolytic activity of factor XIIa at a concentration of 5 X mom in the presence of dextran sulfate (2 pg/mL) and HK (0.7 pmol/L; data not shown). However, the AI domain peptide (Glu'-Serg") did not inhibit the amidolytic activity of factor XIIa at a concentration of up to m o m in the presence of dextran sulfate (2 pgl mL) and HK (0.7 pmol/L; data not shown).
Effects of heavy chain-derived peptides on the activation of factor XI by factor XIla in the presence of dextran sulfate. Because of the effect of kaolin on the amidolytic activity of factor XIIa, we reexamined the effect of heavy chain-derived factor XI peptides using the negatively charged surface, dextran sulfate, which does not affect the amidolytic activity of factor XIIa. The results are presented in Fig 3 and are summarized in Table 1 . Peptide Ala317-Glf50 from the A4 domain inhibited factor XI activation by factor XIIa by 50% at a concentration of 7.5 X mol/L, whereas the recombinant A1 domain peptide (Glu'-Serg0) required a concentration of 5 X lo-' m o m for a similar effect (Fig 3) . When used in combination at equimolar concentrations, these two peptides proved to be an order of magnitude more effective (Ki = 7.5 X mom) than either one alone in inhibiting the surface-mediated activation of factor XI by factor XIIa. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From Ala'76), and the other half of the A4 ( A~p~~~-G l y *~~) domains required 100-fold higher concentrations for similar effects.
DISCUSSION
Factor XI participates in the contact phase of blood coagulation and interacts directly with HK, factor IX, and factor XIIa. Studies in our laboratory have identified and characterized the amino acids within the first two Apple domains of the factor XI heavy chain that form binding sites for HK and factor IX.3,4,5 Recently, we have determined that a sequence of amino acids in the A4 domain of factor XI comprises a site for interacting with factor x11a.l~ It is well documented that negatively charged surfaces accelerate the rate of activation of factor XI by factor XIIa in the presence charged surfaces and HK facilitate this interaction i s not understood. Therefore, the present study was undertaken to determine what domains of factor XI are involved in the surface-mediated reactions and to gain insight into the nature of the interactions between factor XI and factor XIIa.
The present study supports the notion that specific sequences exposed on the surfaces of the A1 domain LysS3) and the A4 domain (Ala317-Gly350) of factor XI act alone and synergistically to promote surface-mediated factor XI activation by factor XIIa in the presence of HK by binding factor XI to surface-bound HK (A1 domain) and by binding factor XIIa near the cleavage site of factor XI (A4 domain). The evidence supporting this conclusion (summarized in part in Table 1 ) is as follows: (1) surface-mediated factor XI activation by factor XIIa was inhibited by an A4 peptide (Ala317-Gly350; Ki = 7.5 X mol/L) and by the A1 peptide of ~~. l . l 1 , 1 6 , 2 8 The precise mechanism by which negatively (Glu'-Ser9'; Ki = 6 X m o m ; see Fig 3) ; (2) when used in combination at equimolar concentrations, A1 (Glul-Sergo) and A4 (Ala317-Gly350) peptides were an order of magnitude more effective (Ki = 6 X mom) than either one alone in inhibiting surface-mediated activation of factor XI by factor XIIa (Fig 3) ; (3) the A4 peptide (Ala317-Gly350) was a competitive inhibitor of factor XIIa amidolytic activity (Ki = 3.8 X mom) and a noncompetitive inhibitor of factor XI activation by factor XIIa (Ki = 3.75 X m0yL)l9 whereas the A1 peptide (Glul-SergO) did not inhibit factor XIIa (data not shown); and (4) the A1 (Glul-Sergo) domain (Ki = mom) inhibited factor XI binding to HK, whereas the A4 peptide (Ala317-Gly350) had no such We have previously shown" that the A4 peptide Ala3I7-Gly350 is a noncompetitive inhibitor of factor-XIIa-mediated factor XI activation in the fluid phase and is a competitive inhibitor of factor XIIa amidolytic activity (Ki = 3.8 X m o m , using the chromogenic substrate S2302. In the present study, we examined the effect of this A4 peptide on the amidolytic activity of factor XIIa in the presence of dextran sulfate. Because the inhibitory effect of Ala3'7-Gly350 (Ki = 5 X mom) in the presence of dextran sulfate is the same as that in the fluid phase and because dextran sulfate does not alter the amidolytic activity of factor XIIa, dextran sulfate is a more suitable surface for the present studies than kaolin, which appears to bind to factor XIIa and inhibit its amidolytic activity (Fig 2) . In contrast to the A4 peptide Ala317-Gly350, the recombinant A1 peptide Glul-Sergo had no effect on the amidolytic activity of factor XIIa in the presence of dextran sulfate. This result further confirms the suitability of dextran sulfate as a surface in these studies. It also supports the notion that the mechanism of action of the A1 domain peptides is limited to its capacity to inhibit binding of factor XI to HK.
The results of our studies provide insights into the mechanisms of surface-mediated factor-XI activation by factor XIIa. Factor XI exists in normal human plasma in a noncovalent complex with HK.7.'6 The binding of this complex to negatively charged surface^^"^.^"'^ Including ' the activated platelet surface29 promotes optimal rates of factor XI activation, presumably by the formation of a ternary complex of HK, factor XI, and factor XIIa.'." As summarized above, peptides derived from the A1 and A4 domains appear to act synergistically to inhibit surface-mediated factor XI activation by factor XIIa, as evidenced by the fact that concentrations of equimolar mixtures of these peptides required to inhibit factor XI activation by factor XIIa in the presence of HK are about 10-fold less than those required when the A1 or A4 peptides are used alone. The mechanisms by which these two sets of peptides act are different, the A1 peptides inhibiting binding of HK to the A1 domain and the A4 peptides inhibiting the binding of factor XIIa to the A4 domain. It follows that the A1 and A4 domains promote synergistic interactions of factor XI with HK and factor XIIa. The mechanism of this synergism is a matter of conjecture. However, it is possible that the binding of HK to the A1 domain induces a conformational alteration in factor XI that renders it a more favorable substrate for factor XIIa. AlternaFor personal use only. on November 11, 2017. by guest www.bloodjournal.org From tively, the binding of the HK-factor XI complex to surface (ie, dextran sulfate) could result in the formation of a surfacebound ternary complex of these proteins with factor XIIa, with a consequent rate enhancement because of favorable positioning of the enzyme (factor XIIa) active site near the substrate (factor XI) cleavage site (Arg'69-Ile370). Another possible explanation of this phenomenon is that HK binding of factor XI to a surface where factor XIIa is bound could also increase the rate of molecular encounters without regard to "favorable positioning." Thus, the rate increase could result from an alteration of the entropy of activation term in the rate constant expression.
Because the four repeat domains (Al, A2, A3, and A4) have a 23% to 34% sequence identity, it was not surprising to see that the A2 and A3 domain peptides inhibit factor XI activation at concentrations 100-to 200-fold higher than those required to obtain similar effects with the A1 and A4 peptides. Because of the similar structural motif of these domains, the A2 and A3 synthetic peptides might disrupt native protein structures and activities by binding to factor XI and thereby disrupting intermolecular domain-domain interactions. We might better understand these effects by producing chimeras of the Apple domains and testing their function.
Our previous ~t u d i e s~'~'~. '~ suggest that a common structural motif present at similar positions within the Al, A2, and A4 domains of factor XI mediates the interactions of factor XI with its plasma ligands, ie, HK (A1 domain), factor IX (A2 domain), and factor XIIa (A4 domain). Our computer modeling studies predict the presence of three loop structures (antiparallel &strands connected by p-turns) in each of the Apple domains that present solvent-accessible amino acid side chains unique to each Apple domain that are used for these highly specific protein-protein interactions. Our studies with conformationally constrained synthetic peptides and recombinant A1 domain peptides confirm our predictions from computer modeling, which tend to support the validity of the paradigm as a predictor of protein-binding surface structures. However, detailed information about the secondary and tertiary structures of the Apple domains of factor XI will have to await the conduction of studies using high-resolution xray crystallography or nuclear magnetic resonance imaging. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From
